Home > Healthcare > Pharmaceuticals > Finished Drug Form > Buccal Drug Delivery Systems Market

Buccal Drug Delivery Systems Market Trends

Report ID: GMI10233
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Buccal Drug Delivery Systems Market Trends

Regulatory agencies are increasingly endorsing buccal drug delivery products, recognizing their proven efficacy and safety. This trend is prompting pharmaceutical companies to invest more in this area and expand their product development efforts.
Furthermore, there is an increasing emphasis on precision medicine within the market. Companies are focusing on developing buccal delivery solutions that can be customized to address the specific needs of individual patients. This approach not only enhances the therapeutic efficacy of treatments but also aligns with the broader healthcare trend of tailoring medical interventions to achieve optimal patient outcomes.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The buccal drug delivery systems market size was valued at USD 3.9 billion in 2023 and is estimated to grow at 8.6% CAGR from 2024 to 2032 due to rising prevalence of chronic diseases and the presence of supportive regulatory landscape.

The buccal films segment in the market recorded a revenue of USD 1.6 billion in 2023, owing to the growing demand for non-invasive and patient-centric drug delivery solutions.

North America buccal drug delivery systems market is forecasted to reach USD 3.2 billion by 2032, propelled by technological advancements, heightened public awareness, and the rising prevalence of chronic diseases.

AbbVie Inc., Amgen Inc., Collegium Pharmaceutical, Inc., Endo International plc, Galderma SA, Indivior plc, Johnson & Johnson Services, Inc., Kyowa Kirin Co., Ltd., Mallinckrodt plc, Neurelis, Inc., and Novartis AG among others.